Complement antagonists and uses thereof
Disclosed are antagonists designed to inhibit or block expression of a mammalian complement such as complement component 6 (C6). The invention has a wide range of uses including use in the preparation of a medicament for the enhancement of nerve regeneration following acute or chronic nerve damage in a mammal. Additional applications include use in the treatment of multiple sclerosis either alone or in combination with another drug.
1. A single-stranded antisense oligomer of between about 10 to 50 nucleotides in length having a contiguous nucleobase sequence with at least 80% sequence identity to a complementary region of a nucleic acid which encodes the COMPLEMENT COMPONENT 6 (C6) sequence represented by SEQ ID NO: 1, or a naturally occurring allelic variant thereof, wherein the oligomer (a) is targeted to about nucleotides 112-152, 433-473, 546-586, 706-746, or 1015-1055 from the ATG start site of SEQ ID NO: 1 (starting at the “A”), (b) comprises at least one nucleotide analogue, and (c) is capable of reducing the level of C6 mRNA expression in a mammal.
2. The oligomer of claim 1 , wherein the oligomer further comprises at least one of a modified internucleoside linkage and a modified nucleobase.
3. The oligomer of claim 1 , wherein the nucleotide analogue is a modified sugar moiety selected from the group consisting of: 2′-O-methoxyethyl modified sugar moiety, a 2′-methoxy modified sugar moiety, a 2′-O-alkyl modified sugar moiety, and a bicyclic sugar moiety.
4. The oligomer of claim 3 , wherein the bicyclic sugar moiety is a locked nucleic acid (LNA) monomer.
5. An antisense oligomer of between about 10 to 50 nucleotides in length having a contiguous nucleobase sequence with at least 80% sequence identity to a complementary region of a nucleic acid which encodes the COMPLEMENT COMPONENT 6 (C6) sequence represented by SEQ ID NO: 1, or a naturally occurring allelic variant thereof, wherein the oligomer (a) is targeted to about nucleotides 112-152, 433-473, 546-586, 706-746, or 1015-1055 from the ATG start site of SEQ ID NO: 1 (starting at the “A”), (b) comprises at least one nucleotide analogue, and (c) is capable of reducing the level of C6 mRNA expression in a mammal, wherein the nucleotide analogue is a locked nucleic acid (LNA) monomer, and wherein the oligomer is a gapmer comprising 2 or 3 LNA monomers at each of the 3′ and 5′ ends of the oligomer.
6. The oligomer of claim 5 , wherein the oligomer further comprises 2′-deoxynucleotides positioned between the 5′ and 3′ wing segments and, optionally, one or both of the 5′ and 3′ ends of the oligomer.
7. The oligomer of claim 2 , wherein the modified internucleoside linkage is a phosphorothioate internucleoside linkage.
8. The oligomer of claim 1 , wherein the modified nucleobase is 5-methylcytosine.
9. The oligomer of claim 1 or 5 , wherein the oligomer is 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 nucleotides in length.
10. The oligomer of claim 9 , wherein the oligomer is between about 10 to about 18 nucleotides in length.
11. The oligomer of claim 1 or 5 , wherein the oligomer has at least 90%, 96%, 97%, 98% or 99% sequence identity to a complementary region of a nucleic acid which encodes the Complement Component C6 sequence represented by SEQ ID NO:1.
12. The oligomer of claim 11 , wherein the oligomer comprises one, two, or three mismatches with respect to the Complement Component C6 sequence represented by SEQ ID NO: 1.
13. A pharmaceutical composition comprising the oligomer of claim 1 or 5 and a pharmaceutically acceptable diluent, carrier, salt or adjuvant.
14. The oligomer of claim 1 or 5 , wherein the oligomer is targeted to about nucleotides 132, 453, 566, 726 or 1035 from the ATG start site of SEQ ID NO: 1.
15. The oligomer of claim 14 , wherein the oligomer has at least 90%, 96%, 97%, 98% or 99% sequence identity to a complementary region of a nucleic acid which encodes the Complement Component C6 sequence represented by SEQ ID NO:1.